An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment by Geurts van Kessel, C.H. (Corine) et al.
ARTICLE
An evaluation of COVID-19 serological assays
informs future diagnostics and exposure
assessment
Corine H. GeurtsvanKessel 1,6✉, Nisreen M. A. Okba 1,6, Zsofia Igloi 1, Susanne Bogers1,
Carmen W. E. Embregts 1, Brigitta M. Laksono1, Lonneke Leijten1, Casper Rokx2, Bart Rijnders2,
Janette Rahamat-Langendoen3, Johannes P. C. van den Akker4, Jeroen J. A. van Kampen1,
Annemiek A. van der Eijk1, Rob S. van Binnendijk5, Bart Haagmans 1 & Marion Koopmans 1
The world is entering a new era of the COVID-19 pandemic in which there is an increasing
call for reliable antibody testing. To support decision making on the deployment of serology
for either population screening or diagnostics, we present a detailed comparison of ser-
ological COVID-19 assays. We show that among the selected assays there is a wide diversity
in assay performance in different scenarios and when correlated to virus neutralizing anti-
bodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding
domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in
different stages and severity of disease, including the potential to set a cut-off indicating the
presence of protective antibodies. The large variety of available serological assays requires
proper assay validation before deciding on deployment of assays for specific applications.
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The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) was first reported in late 2019 to causecoronavirus disease (COVID-19). The rapid global spread
and exponential growth of the pandemic wave have stretched the
limits of the available healthcare and intensive care unit capacity.
Since the initial notification of an outbreak on December 31st,
the global response has transitioned from the initial policy of
active case finding and containment to an increasingly complex
package of confinement measures including closures of schools,
implementation of travel restrictions, and physical distancing
measures. At present, given the global circulation of SARS-CoV-
2, the consensus is that elimination of the virus is no longer
feasible, and that longer-term strategies are needed that strike a
balance between the economically and socially damaging (near)
lockdown approaches and full release of any control measures.
There is wide agreement that, in the latter situation, rapid
resurgence would be very likely, with modeled epidemic peaks
potentially exceeding the current healthcare capacity1.
The so-called exit strategy is defined as the transition from the
current approach, which focuses entirely on flattening the peak of
the COVID-19 emergence curve, to the transition phase in which
restrictions are gradually lifted. The gradual lifting of control
measures will require active surveillance to allow early detection
of new cases or clusters, coupled with contact tracing and quar-
antine, most likely combined with continued physical distancing
recommendations and enhanced protection of those at-risk from
most severe disease. A key knowledge gap is the level and dura-
tion of protective immunity in the population at large and in
specific groups, including persons with different clinical
severity1,2.
To assess the extent of virus circulation in the community, and
the likelihood of protection against a re-infection, there is a
crucial need to add serology to the testing algorithms. The
required performance of a serological assay will depend on the
specific aim of testing, which may be either population screening
(in the general population or at-risk populations) or diagnostic
support. We recently showed that antibodies directed against the
S1 subunit of the SARS-CoV-2 spike protein and specifically to
the receptor binding domain (RBD) within the S1 subunit
strongly correlate with virus neutralization3. The likelihood of
predicting protective antibody responses will thus increase when
using either S1 antigens or RBD in the assay. The specificity of
serological tools detecting antibodies against SARS CoV-2 might
be hampered by the presence of antibodies against other circu-
lating coronaviruses in the population, and thus testing for cross
reactivity is crucial. When selecting an appropriate assay for a
specific purpose, decision making should include the available
knowledge on antibody specificities, kinetics, and functions4. The
limited knowledge on antibody kinetics in emerging virus infec-
tions is always a challenge for design and validation of serological
assays during an outbreak. Recent studies in COVID-19 patients
have shown that in both hospitalized patients and patients with
mild disease, seroconversion rates reach 100% after 10–14 days,
and that antibody levels may correlate with clinical severity2,3,5.
This is in line with observations in Middle East Respiratory
Syndrome coronavirus (MERS-CoV) infection, in which antibody
responses varied depending on disease severity, with mild and
asymptomatic infections resulting in weaker immune responses6.
Therefore, for meaningful interpretation of serological assays and
extrapolation of results to population screening, sufficient sam-
ples from persons with mild and asymptomatic disease should be
included in validation studies.
In our study we compare three platforms, which are widely
used in diagnostic laboratories (three rapid tests, four ELISAs,
and a high throughput chemiluminescent assay (CLIA)), which
can be used to address different needs: for individualized (home)
testing, as supplement to diagnostics and in population screening.
We analyze their performance in correlation to an in-house virus
neutralization assay3, which is currently the gold standard when
assessing protective immunity against SARS CoV-2.
Results
Patient diagnostics. Serological testing to support clinical diag-
nostic work-up is mostly requested in hospitalized patients. This
can be for example when SARS CoV-2 RNA diagnostic testing
remains negative in a patient despite a strong clinical suspicion or
for patients whose samples during the symptomatic phase were
not collected. Other patients in whom antibody testing can be
very valuable are those who have been hospitalized for weeks and
in whom a PCR test continues to be positive with increasing cycle
threshold values. In these patients, the detection of virus neu-
tralizing antibodies can help with the decision to stop using
personal protective equipment. In these patients usually the ser-
ological results are interpreted by laboratory staff and there is a
possibility to test follow-up sera or perform confirmation ser-
ological testing. When comparing the laboratory assays in
patients with different severity and stages of disease (overall), and
in patients tested more than 14 days post-onset of disease, the
RBD antigen based Wantai total Ig assay performed best (Fig. 1,
Table 1). Both IgG assays targeting the S antigen (Euroimmun
and Liaison) lacked sensitivity in hospitalized patients as the
sample set included early time-points. The S1 based IgA assay by
Euroimmun, in contrast, had a good sensitivity, and showed the
best quantitative relationship, specifically once neutralizing titers
were higher than 80 (PRNT50 units), upon which the RBD Ig
assay becomes non-linear. IgA testing will detect both early and
memory IgA responses and will thus be a useful addition to IgG
assays. The possible relevance of quantitative antibody measure-
ments will need to be assessed when results of longer-term patient
follow-up studies become available. An alternative of the PRNT50
can be the use of a surrogate virus neutralization test for SARS
CoV-2 (as recently produced by Genscript, USA) which allows
direct quantification. Extensive studies on the performance have
however not yet been published.
Despite the differences in sensitivity, all laboratory assays had
sufficient positive predictive value (PPV) in COVID-19 hospita-
lized patients when assuming an expected seroprevalence in this
population of ≥50% (Table 1), or when using serology as an
adjunct to RT-PCR testing to monitor the clinical course of
illness. Their application as sole diagnostic, however—for
instance in primary care, where the seroprevalence will be much
lower—will be more challenging as illustrated by the variation in
PPV of the assays with a seroprevalence estimate of 4%, which is
the level currently observed in the Netherlands7.
In addition to specialized ELISA assays used in laboratory
settings, a wide range of rapid diagnostic tests (RDT) has been
put on the market, triggering the question whether they can be
used in patient care or for triage in a medical care facility. We
selected three RDTs by following criteria (1) preferably targetting
the spike of SARS-CoV-2 (2) at least European Conformity (CE)
marking or other authorization, and (3) sufficient production
capacity. The RDTs provide qualitative (yes/no) results, which
does not allow quantification or the definition of a cut-off for
neutralization (Fig. 1f–h). All three RDTs had a sufficient PPV in
high seroprevalence scenarios, which implies that there might be
a role for the RDTs when used for the individual patient with a
sufficiently high pretest probability as an add on to PCR based
diagnostics. The high negative predictive value (NPV) of the
RDTs in a low seroprevalence scenario could offer opportunities
for the use of the test in the general population, if the aim is to
rule out the presence of SARS CoV-2 antibodies (Table 1).
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Population screening. Population screening during a pandemic
phase requires a highly specific assay, to assure an acceptable PPV
in populations with a low sero-prevalence3, and additionally a
reasonable sensitivity (Table 1). This condition was met for the
Wantai ELISAs and Euroimmun IgG ELISA. The Euroimmun
IgA and Liaison CLIA analyzer performed less well, with spe-
cificities <95% when testing serum samples from persons exposed
to a range of viruses (Table 1)8. This led to very low PPV’s of
respectively 39% and 26% for the Euroimmun IgA and the CLIA
analyzer in low prevalence settings, while the Wantai total Ig
continued to perform reasonably well. Tested specimen were
obtained from patients with mild, moderate, and severe disease.
All patients had detectable antibodies by PRNT50 from day 18
(supplementary data). The severity of disease did not affect the
range of detected neutralizing titers or sensitivity of selected
assays (Table 1, supplementary data). Due to limitations in
sample volumes of mild patients, these were not equally tested in
all assays. In addition, future studies are recommended to address
the performance of alternative high throughput assays like the
Roche Elecsys Anti-SARS-CoV-2 or Abbott SARS-CoV-2 IgG, in
correlation to neutralization.
For the RDTs the specificities varied from 85 to 99% (Table 1),
although the overall performance of the Cellex assay with 99%
specificity was hampered by its low sensitivity of 80%. Generally,
the use of the selected RDT is not recommended in population
screening where estimated seroprevalence is mostly <5% and the
PPV will be too low for a reliable interpretation (Table 1). A final
question in population screening is whether the antibody
measurements correlate with functional antibodies that can
protect a population during a subsequent exposure. In our
analyses, samples testing positive in the Wantai Ig ELISA with an
OD ratio > 10 all had detectable levels of neutralizing antibodies
which suggests that—using a cut-off- in this assay could be used
to indicate presence of neutralizing antibodies. The exact kinetics
and functionality of these antibodies in offering protection
remains to be determined.
In conclusion, our presented data support decision making for
the use of serology in either individual patient care or population-
level serological testing. We conclude that for the aim of detecting
protective antibodies, the RBD based Wantai ELISA had the best
overall performance including the potential to set a cut-off
indicating the presence of protective antibodies. The global
performance of the selected RDTs is not robust enough for over
the counter personalized testing in the population.
Methods
Blood samples. All specimen used in the study have been collected and delivered
to our diagnostic laboratory for patient diagnostics, and not following a predefined
COVID-19 research protocol. To determine specificity of the assays, we used a
well-defined panel of 147 serum and plasma samples from 147 individuals exposed
to human coronaviruses (HCoV-229E, NL63 or OC43), SARS, MERS), or with a
range of other respiratory viruses (adenovirus, human metapneumovirus, influenza
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Fig. 1 Performance of commercial assays for the detection of SARS-CoV-2-specific antibodies. Correlation of SARS-CoV-2 neutralizing antibody titers
tested by a plaque reduction neutralization assay (PRNT50) to antibodies measured by selected assays. (a) Wantai Ig total ELISA, (b) Wantai IgM ELISA,
(c) Euroimmun IgG ELISA, (d) Euroimmun IgA ELISA, (e) DiaSorin Liaison XL IgG chemiluminescence immunoassay, (f) Cellex IgM/IgG, (g) InTec IgM/
IgG, (h) Orient gene/Healgen IgM/IgG. Turquoise dots indicate patient specimen collected ≤7 days post onset of symptoms (dps), magenta dots
indicate samples collected from 8–14 dps, gray dots indicate specimen collected more than 14 dps. Dotted lines indicate the cut-off for positivity of each
assay, as indicated by the manufacturer: Wantai ELISAs, OD ratio > 1; Euroimmun ELISAs, OD ratio > 1.1; DiaSorin Liaison IgG >15 AU/ml. OD: optical
density, AU: arbitrary units, r: correlation coefficient. (i) Percentages of specificities and sensitivities of the various platforms tested. The arrow bar
indicates the upper and lower limit of the 95% CI. Source data are provided as a Source Data file.
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Specimen from patients with recent cytomegalovirus (CMV), Epstein Barr virus
(EBV) or M. pneumoniae infection were included as these have a high likelihood of
causing cross reactivity. Sera were collected from 2–3 weeks upon the respiratory
infection, and during the acute phase of CMV or EBV. The variation in the number
of samples tested per assay was caused by limited sample volume and by the
limited availability of RDTs during the study period.
Sensitivity was calculated by using a total of 187 sera from 107 individuals in the
Netherlands, in whom COVID-19 was confirmed by RT-PCR and antibodies were
detected by PRNT50. Disease severity varied from (1) Mild, non-hospitalized, (2)
Moderate, hospitalized, and (3) Severe, admitted to the intensive care unit.
Specimen were taken at different time-points post-onset of disease (supplementary
data, Fig. 1). All specimen were stored at −20 °C until use. The variation in the
number of samples tested per assay is caused by the fact that validation was part of
the acute diagnostic response during the first phase of the COVID-19 pandemic.
Initially, a set of 75 patient sera was tested in all assays. These sera were mostly
collected from hospitalized patients and involved only three sera from mild
patients. To assess the performance of the assays in population screening it is
important to involve sera from mild patients so we increased the number of tested
sera in the Wantai ELISAs, Liaison, and RDTs. The selection of these assays was
based on the best overall performance of Wantai ELISAs in the first analyses
and the likely application of Liaison and RDTs in population screening. The
exact number of specimen tested per assay varied due to availability of serum.
Figure 1 depicts the outcome of the assays per time interval, analyses in mild
patients are shown in Table 1, source data can be found in the Supplementary
Data 1.
Ethics declarations. The use of specimen was approved by the Erasmus
MC medical ethical committee (MEC approval: 2014–414), which allows the use of
clinical data and left-over material from the specimen delivered to our laboratory
for diagnostics, unless patients have declared they opted out of this scheme. In
addition, the Erasmus MC institutional research committee regulated that all
COVID-19 patients admitted to Erasmus MC are asked for permission to use their
clinical data and left-over patient material for COVID-19 research purposes. All
patients who refused have been excluded from the analyses.
ELISA. Four selected ELISAs were performed according to manufacturer’s proto-
col: (1) Wantai SARS-CoV-2 total Ig and IgM ELISAs from Beijing Wantai Bio-
logical Pharmacy Enterprise Co., Ltd., China. The ELISAs are coated with RBD
antigen. (2) Euroimmun Anti-SARS-CoV-2 IgG and IgA ELISA assays
from EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany. The
Euroimmun ELISAs are coated with S1 antigen.
DiaSorin Liaison XL. The Liaison XL by DiaSorin (Saluggia, Italy), is a semi-
automated system using chemiluminescent immunoassay (CLIA) technology for
detection of Ab in human samples. The assay is based on S1 and S2 coating
antigens. The assays were performed following manufacturer’s protocol.
Rapid antibody test. The rapid tests we evaluated are (1) Rapid SARS -CoV-2
Antibody (IgM/IgG) Test from InTec utilizing the nucleocapsid protein as antigen
(Test lots S2020021505 and GJ20030288), (2) the qSARS-CoV-2 IgG/IgM Cassette
Rapid Test (GICA) from Cellex Inc. utilizing both the spike and the nucleocapsid
protein (Test lot 20200416WI5513C) and (3) the COVID-19 IgG/IgM Rapid Test
Cassette (Whole Blood/Serum/Plasma) from Orient Gene / Healgen (Test lot
2003309), utilizing both the spike and the nucleocapsid protein. All three tests are
based on immunochromatography for detection of IgG and IgM specific to SARS
CoV-2 in human whole blood (venous and fingerstick) serum or plasma. We per-
formed the tests following the manufacturers’ instructions. Each sample was tested by
one test and readout (positive/negative) interpreted by two operators in parallel.
PRNT 50. An in-house plaque-reduction neutralization test (PRNT50) was used as
a reference for this study, because virus neutralization assays are the gold standard
in coronavirus serology. We tested serum and plasma samples for their neu-
tralizing capacity against SARS-CoV-2 (German isolate; GISAID ID EPI_ISL
406862; European Virus Archive Global # 026V-03883) by PRNT50 as previously
described by Okba et al.3.
Statistical analysis. The outcome of commercial testing was correlated to func-
tional antibody measurements, to assess likelihood of predicting protective anti-
body responses. The results of the different ELISAs and RDTs were compared with
those detected by PRNT50. For sensitivity calculations only the PRNT50 positive
samples were used for the calculations. Specificity was calculated by using the cross
reactive panel of non-SARS CoV-2 sera. Graphs were made by using GraphPad
Prism version 8 (https://www.graphpad.com). The predictive values were calcu-
lated for three scenarios 4% seroprevalence in a general population, 50% ser-
oprevalence in a high-risk sub-population and 95% seroprevalence in confirmed or
highly suspect COVD-19 hospitalized patients.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Source data are provided with this paper. Other data are available from the
corresponding author upon reasonable requests. Source data are provided with
this paper.
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Table 1 A summary of the performance characteristics of eight commercial COVID-19 serology assays.
Assay Wantai Ig Wantai IgM Euroimmun IgG Euroimmun IgA Liaison Cellex Intec Orient/Healgen
Platform ELISA ELISA ELISA ELISA CLIA RDT RDT RDT
Antigen RBD RBD S1 S1 S1 and S2 S and N N S and N
Specificity
n/N 145/146 144/146 156/157 147/157 119/132 97/98 83/98 87/98
Value 0.99 0.99 0.99 0.94 0.90 0.99 0.85 0.88
95% CI 0.96–1.0 0.951–1.0 0.97–1.0 0.89–0.97 0.84–0.95 0.95–1.0 0.76–0.91 0.80–0.94
Sensitivity
Overall n/N 186/187 167/185 61/75 73/75 134/165 101/113 102/113 113/113
Value 0.99 0.90 0.81 0.97 0.81 0.89 0.90 1.0
95% CI 0.97–1.0 0.85–0.94 0.71–0.89 0.91–1.0 0.74–0.87 0.82–0.94 0.83–0.95 0.97–1.0
>14 dps n/N 117/117 100/115 26/27 27/27 95/104 63/67 55/65 67/67
Value 1.0 0.87 0.96 1.0 0.91 0.94 0.84 1.0
95% CI 0.97–1.0 0.79–0.93 0.81–1.0 0.87–1.0 0.84–0.96 0.85–0.98 0.74–0.92 0.95–1.0
Mild n/N 64/64 54/62 1/3 3/3 46/55 33/37 26/36 37/37
Value 1.0 0.87 0.33 1.0 0.84 0.89 0.72 1.0
95% CI 0.94–1.0 0.76–0.94 0.0084–0.91 0.29–1.0 0.71–0.92 0.75–0.97 0.55–0.86 0.91–1.0
Overall PPV
Population prevalence 4% 0.86 0.73 0.84 0.39 0.26 0.78 0.20 0.26
50% 0.99 0.99 0.99 0.94 0.89 0.99 0.86 0.89
95% 1.0 1.0 1.0 1.0 0.99 1.0 0.99 0.99
Overall NPV
Population prevalence 4% 1.0 1.0 0.99 1.0 0.99 1.0 1.0 1.0
50% 0.99 0.91 0.84 0.97 0.83 0.9 0.9 1.0
95% 0.91 0.35 0.22 0.65 0.20 0.33 0.31 1.0
Sensitivity of the assays was determined by comparing the outcome to virus neutralization (PRNT> 20). Patients were considered mild if they have not been admitted to a hospital. The PPV was
calculated for 3 scenarios: 4 % seroprevalence in a general population. 50% seroprevalence in a high risk sub-population and 90% seroprevalence in hospitalized patients suspect for COVID-19. Ig:
immunoglobulin, ELISA: enzyme linked immunosorbent assay, CLIA: chemiluminescence immune assay, RDT: rapid diagnostic test, n:number of positives, N: total number tested, CI: confidence interval,
dps: days post onset of symptoms, PPV: positive predictive value, NPV: negative predictive value, PRNT: plaque reduction neutralization test.
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